Evidence map›Paper›PMID 40801430›Full record

ReviewCPT: pharmacometrics & systems pharmacology2025

Mathematical Modeling of Neuroinflammation in Neurodegenerative Diseases.

Alex Foster-Powell, Amin Rostami-Hodjegan, Guy Meno-Tetang, Donald E Mager, Kayode Ogungbenro

Abstract readReview
In one paragraph

Review in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. WhenAPL bioengineering · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alex Foster-PowellCAPKR, University of Manchester, Manchester, UK.ORCID 0000-0002-0708-8434
Amin Rostami-HodjeganCAPKR, University of Manchester, Manchester, UK.ORCID 0000-0003-3917-844X
Guy Meno-TetangNeuroscience R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-2631-3705
Donald E MagerDepartment of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.ORCID 0000-0002-4848-0440
Kayode OgungbenroCAPKR, University of Manchester, Manchester, UK.ORCID 0000-0003-2446-6895

Funding

Biotechnology and Biosciences Research Council (BBSRC) Industrial CASE studentship in collaboration with AstraZeneca (AZ), UK BB/W509930/1
6 · The paper itself

Abstract

Age-related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD) are an increasing public health concern. Whereas the pathology of these diseases is complex, chronic central inflammation, or neuroinflammation, is commonly observed across many neurodegenerative diseases. Despite a huge wealth of resources and promising preclinical testing, effective disease-modifying therapies do not exist. This failure is owing to a combination of poor biological understanding of this response, unsuitable animal models, and poor scaling from pathway up to clinical levels. In order to address these challenges, systems-level mathematical models may be utilized. Here, we provide a background on neuroinflammation and summarize available mathematical models of this response. Models described by ordinary, partial, and delay differential equations, and Boolean logic are introduced and discussed. The results as discussed in this review suggest logic-based modeling as a formalism capable of managing the challenges associated with the modeling of CNS diseases.

Indexed as

InflammationModels, BiologicalModels, TheoreticalNeurodegenerative DiseasesNeuroinflammatory DiseasesAnimalsHumansAlzheimer's diseasemathematical modelingmicroglianeurodegenerative diseaseneuroinflammationParkinson's diseaseQSP

Identifiers

PMID40801430
PMCPMC12706407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.